Literature DB >> 8764174

Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27.

M A Lee1, M Böhm, M Paul, M Bader, U Ganten, D Ganten.   

Abstract

Transgenic techniques represent powerful tools for the study of gene-related mechanisms of diseases such as hypertension, which results from a complex interaction between genetic and environmental factors. The renin-angiotensin system, a biochemical cascade in which renin functions as the key enzyme in the formation of the effector peptide angiotensin II, plays a major role in the regulation of blood pressure. The renin gene, therefore, represents an important candidate gene for hypertension. Because rats are more suited than mice for a number of experimental settings often employed in cardiovascular research, we modified the transgenic technique to generate the transgenic rat strain TGR(mREN2)27 harboring the murine Ren-2 gene. These transgenic rats develop fulminant hypertension at an early age despite low levels of renin in plasma and kidney. In addition, high expression of the transgene in a number of extrarenal tissues is associated with increased local formation of angiotensin II. Thus the TGR(mREN2)27 rat represents a model of hypertension with a defined genetic background. Studies on the transgenic rat may not only provide new insights into pathophysiological mechanisms of hypertension in this animal model but also offer the unique possibility to investigate the function and regulation of renin-angiotensin systems in extrarenal tissues. The aim of this review is to compile the knowledge that has been accumulated to date on this transgenic rat and to discuss possible mechanisms responsible for its hypertensive phenotype.

Entities:  

Mesh:

Year:  1996        PMID: 8764174     DOI: 10.1152/ajpendo.1996.270.6.E919

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  28 in total

1.  Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive ((mRen-2)27) rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Central depletion of angiotensinogen is associated with elevated AT1 receptors in the SFO and PVN.

Authors:  Sherry O Kasper; Carlos M Ferrario; Detlev Ganten; Debra I Diz
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

3.  Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.

Authors:  Tom Nijenhuis; Alexis J Sloan; Joost G J Hoenderop; Jan Flesche; Harry van Goor; Andreas D Kistler; Marinka Bakker; Rene J M Bindels; Rudolf A de Boer; Clemens C Möller; Inge Hamming; Gerjan Navis; Jack F M Wetzels; Jo H M Berden; Jochen Reiser; Christian Faul; Johan van der Vlag
Journal:  Am J Pathol       Date:  2011-08-11       Impact factor: 4.307

4.  Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat.

Authors:  Vincent G DeMarco; Megan S Johnson; Javad Habibi; Lakshmi Pulakat; Rukhsana Gul; Melvin R Hayden; Roger D Tilmon; Kevin C Dellsperger; Nathaniel Winer; Adam T Whaley-Connell; James R Sowers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-05       Impact factor: 4.733

5.  Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism.

Authors:  Maggie K Diamond-Stanic; Erik J Henriksen
Journal:  Arch Physiol Biochem       Date:  2010-05       Impact factor: 4.076

6.  Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system.

Authors:  Sarka Varcabova; Zuzana Huskova; Herbert J Kramer; Sung Hee Hwang; Bruce D Hammock; John D Imig; Kento Kitada; Ludek Cervenka
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-04       Impact factor: 2.557

7.  Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.

Authors:  Rudolf A de Boer; Saraswati Pokharel; Markus Flesch; Derk A van Kampen; Albert J H Suurmeijer; Frans Boomsma; Wiek H van Gilst; Dirk J van Veldhuisen; Yigal M Pinto
Journal:  J Mol Med (Berl)       Date:  2004-08-20       Impact factor: 4.599

8.  Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats.

Authors:  Vera Certíková Chábová; Agnieszka Walkowska; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Petr Kujal; Zdenka Vernerová; Zdena Vanourková; Libor Kopkan; Herbert J Kramer; John R Falck; John D Imig; Bruce D Hammock; Ivana Vanecková; Ludek Cervenka
Journal:  Clin Sci (Lond)       Date:  2010-02-23       Impact factor: 6.124

Review 9.  Galectin-3 in cardiac remodeling and heart failure.

Authors:  Rudolf A de Boer; Lili Yu; Dirk J van Veldhuisen
Journal:  Curr Heart Fail Rep       Date:  2010-03

10.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.